Please enable Javascript
ASTRO 2022: Focus on Prostate Cancer
Advertisement
RGPT for Prostate Cancer Is Generally Effective
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 25, 2022
RGPT is reliable in terms of safety and short-term clinical outcomes in patients with prostate cancer.
Read More
Assessing PSMA PET Uptake in Prostate Cancer Following Radiation
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 25, 2022
Researchers assessed the kinetics of PSMA PET uptake in prostate cancer lesions following radiation therapy.
Read More
HDR Brachytherapy in Prostate Cancer: Pros and Cons
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 25, 2022
HDR brachytherapy as a salvage local therapy in prostate cancer has pros and cons.
Read More
High ATM Expression Linked to Worse Outcomes in Patients With Prostate Cancer
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 25, 2022
Researchers observed that patients with prostate cancer with high ATM have worse outcomes.
Read More
Looking at the Pattern of Radiotherapy Treatment Modalities for Prostate Cancer
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
A study compared the use of different radiation therapy (RT) techniques in prostate cancer.
Read More
Does Dose-Intensified Radiation Therapy Increase Survival in Prostate Cancer?
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
Dose-intensified radiation therapy does not yield increased survival in prostate cancer compared with today treatment.
Read More
Assessing BF in Patients With Prostate Cancer Treated With Radiation
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
The risk of biochemical failure (BF) increases over time for patients with prostate cancer initially treated with radiation.
Read More
Decline of PSA Screening Rates Linked to Higher Rates of Metastatic Prostate Cancer
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
A new study shows that lower facility-level PSA rates are linked with higher rates of metastatic prostate cancer.
Read More
Assessing Ga-68-PSMA PET/CT as a Biomarker in Prostate Cancer
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
A study assessed Ga-68-PSMA PET/CT as a biomarker in prostate cancer.
Read More
Study Finds Optimal Duration of Androgen Deprivation Therapy for Prostate Cancer
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
A study identified the optimal androgen deprivation therapy (ADT) duration to enhance survival in prostate cancer.
Read More
PSMA PET: An Important Tool for Prostate Cancer Treatment Planning
Robert Dillard
ASTRO 2022: Focus on Prostate Cancer
|
October 24, 2022
PSMA PET is an important tool for postoperative treatment planning in prostate cancer (PCa) according to a study.
Read More
Advertisement
Advertisement
Advertisement